Sequenom announced that the American College of Obstetricians and Gynecologists, or ACOG, Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee issued a joint Committee Opinion on November 20, recommending that cell-free fetal DNA testing be offered to patients at increased risk of aneuploidy. It can also be used as a follow-up test for women with a positive first-trimester or second-trimester screening test result. Previously, the ACOG recommended that women, regardless of maternal age, be offered prenatal assessment for aneuploidy by screening or invasive prenatal diagnosis, Sequenom added. "The issuance of the ACOG/SMFM opinion on the use of cell-free fetal DNA testing represents a major step forward for the integration of this valuable technology into pregnancy care programs" said Allan Bombard, MD, Sequenom's Chief Medical Officer. Sequenom's MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13 and Y chromosomal material in cell-free DNA.